Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534101 | 0.84 | ALDH1A1 (0.44) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL3868497 | 0.81 | LPAR3 (0.52) | — | |
| SCHEMBL29155307 | 0.81 | LPAR3 (0.52) | — | |
| SCHEMBL29007221 | 0.81 | LPAR3 (0.52) | — | |
| SCHEMBL27511763 | 0.81 | LPAR3 (0.52) | — | |
| SCHEMBL30360777 | 0.81 | LPAR3 (0.52) | — | |
| SCHEMBL277856 | 0.78 | LPAR3 (0.48) | — | |
| SCHEMBL7156934 | 0.78 | PPARD (0.34) | — | |
| SCHEMBL28500058 | 0.76 | LPAR3 (0.41) | GABBR2GABBR1GABRR1 | |
| SCHEMBL4717100 | 0.75 | LMNA (0.46) | LMNABLMCYP3A4NFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5641762-A | TREATING DEGENERATIVE BONE DISORDERS BY ADMINISTERING COMPOUND FORMED BY REACTING BRIDGING AGENT WITH CARBONIC ANHYDRASE INHIBITOR, THEN WITH BONE SEEKING AGENT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-06-24 | — | — | US | claimed |
| EP-1697302-A1 | COMPOUNDS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF BONE INJURY AND METABOLIC DISORDERS | University of Louisville Research Foundation (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005066114-A1 | COMPOUNDS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF BONE INJURY AND METABOLIC DISORDERS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050143366-A1 | Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2005-06-30 | — | — | US | disclosed |
| US-5641762-A | TREATING DEGENERATIVE BONE DISORDERS BY ADMINISTERING COMPOUND FORMED BY REACTING BRIDGING AGENT WITH CARBONIC ANHYDRASE INHIBITOR, THEN WITH BONE SEEKING AGENT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143366-A1 | Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders | SOST, BMP2, BMP4 | LMNA 957/4885BLM 2299/4885CYP3A4 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.